Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06835569 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
A Phase 1 study of Cancer and Advanced Solid Tumors, sponsored by Alterome Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 188
- Enrollment target
- 9
- Study locations
NCT06835569: Recruiting Phase 1 study of Cancer and Advanced Solid Tumors, sponsored by Alterome Therapeutics.
NCT06835569 is a Phase 1 study of Cancer and Advanced Solid Tumors that is actively recruiting participants, run by Alterome Therapeutics. The registered enrollment target is 188 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06835569, a Phase 1 study of Cancer and Advanced Solid Tumors, is actively recruiting participants, sponsored by Alterome Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 188 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
Primary Outcome
Number of participants that experience treatment-emergent adverse events (TEAEs).
Conditions Studied
Interventions
- DRUG cetuximab
- DRUG ALTA3263
Study Locations (9)
Texas
- Research Site - Houston
- Research Site #2 - San Antonio
- Research Site - San Antonio
Massachusetts
- Research Site - Boston
- Research Site - Boston
Florida
- Research Site - Orlando
New York
- Research Site - New York
Tennessee
- Research Site - Nashville
Virginia
- Research Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2029-08 |
| Phase | Phase 1 |
What NCT06835569 shows while recruiting
NCT06835569 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower).
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which cetuximab is the first listed.
NCT06835569 lists 9 locations in 6 states (Texas, Massachusetts, Florida).
Frequently Asked Questions
What is clinical trial NCT06835569 about?
NCT06835569 is a clinical study titled "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations". The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
What is the current status of trial NCT06835569?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 188 participants. The study started on 2025-03-05. Estimated completion is 2029-08.
What conditions does trial NCT06835569 study?
This clinical trial studies the following conditions: Cancer, Advanced Solid Tumors, NSCLC (Non-small Cell Lung Cancer), PDAC - Pancreatic Ductal Adenocarcinoma, CRC, Colorectal Cancer.
What interventions are being tested in trial NCT06835569?
The interventions under investigation include: cetuximab (DRUG), ALTA3263 (DRUG).
Who is sponsoring clinical trial NCT06835569?
This trial is sponsored by Alterome Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06835569 being conducted?
This trial has 9 study locations across Florida, Massachusetts, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06835569's enrollment target sits among peer trials
188 242nd of 615 higher than 371 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI